Collectively, our data suggest that an A2aR antagonist would be a proper treatment to inhibit Treg activity in sepsis and consequently enhance neutrophil phagocytosis and ROS generation function to enhance bacterial clearance and improve the survival rate. This evidence concerns the gene ADORA2A and Sepsis.